XNAS · Healthcare · Diagnostics & Research
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
**Delisting notice** from Nasdaq due to stockholders' equity below $2.5M minimum threatens survival of this $6M ultrasound diagnostics developer. EPS beat meaningless given existential listing crisis.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | Q1 2026 | -1.23 | -1.09 | +11.38% | $0 | ✅ Beat | -0.99% | -3.88% | — |
| 2026-03-31 | Q4 2025 | -1.23 | -3.25 | -164.23% | $0 | ❌ Miss | +1.51% | +14.84% | +4.73% |
| 2025-11-17 |
| Q3 2025 |
| -1.95 |
| -2.10 |
| -7.69% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-03-31 | Q4 2024 | — | -7.35 | — | $0 | — | -4.39% | +6.83% | +46.59% |
| 2024-11-15 | Q3 2024 | -70.00 | -333.90 | -377.00% | $0 | ❌ Miss | -8.15% | +12.11% | -3.30% |
| 2024-08-14 | Q2 2024 | -122.50 | -140.00 | -14.29% | $0 | ❌ Miss | -5.63% | -83.78% | -91.65% |
| 2024-05-14 | Q1 2024 | -472.50 | -455.00 | +3.70% | $0 | ✅ Beat | +0.28% | +4.56% | -65.14% |
| 2024-03-28 | Q4 2023 | -630.00 | -297.50 | +52.78% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.